Sermorelin Manufacturing, Supply and Shortage History: What Women Need to Know

What Sermorelin Is and How It Works

Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It contains the first 29 amino acids of endogenous GHRH, which is the biologically active fragment needed to bind the GHRH receptor on pituitary somatotroph cells and trigger growth hormone (GH) secretion.

The receptor-level mechanism

When sermorelin binds the GHRH-R, it activates adenylyl cyclase, raises intracellular cyclic AMP, and causes pulsatile GH release within minutes. That GH then travels to the liver and peripheral tissues, where it stimulates insulin-like growth factor 1 (IGF-1) production. IGF-1 is the downstream marker clinicians use to assess whether sermorelin is working.

Unlike recombinant human growth hormone (rhGH), which bypasses the pituitary entirely, sermorelin works upstream. The pituitary still governs the pulse. This means somatostatin-mediated negative feedback remains active, which is one reason sermorelin is considered to carry a lower risk of GH excess than direct rhGH injection.

Why the 29-amino-acid fragment matters

Full-length GHRH has 44 amino acids. The truncated 1-29 form (sermorelin) retains full receptor affinity but has a shorter plasma half-life of roughly 10 to 20 minutes. That brief window is why the standard clinical instruction is to inject just before sleep, when the largest endogenous GH pulse normally occurs, amplifying the physiological rhythm rather than overriding it.

How GH physiology differs in women

This part rarely appears in general sermorelin content, and it matters. Women secrete GH in higher pulse amplitude than men across reproductive years, driven partly by estrogen's stimulatory effect on the pituitary. Estradiol upregulates GHRH receptor expression and augments GH pulse amplitude, meaning the same sermorelin dose may produce a proportionally larger GH response in a premenopausal woman than in a man of similar weight.

In perimenopause and postmenopause, estrogen drops and GH pulse amplitude falls with it. A 50-year-old postmenopausal woman may have a blunted sermorelin response compared with her premenopausal self, which has direct implications for dosing and for interpreting post-injection IGF-1 levels. The Endocrine Society's clinical practice guideline on GH deficiency in adults notes that women generally require higher rhGH doses than men to achieve equivalent IGF-1 targets, likely because oral estrogen (but not transdermal) attenuates hepatic GH sensitivity. The same sex difference almost certainly applies to sermorelin, though no head-to-head trial has tested this directly.

The Regulatory and Manufacturing History of Sermorelin

Understanding the supply situation requires a short history of how sermorelin went from FDA-approved drug to compounded peptide.

The Geref era: 1997 to 2008

Sermorelin acetate (brand name Geref Diagnostic, manufactured by Serono Laboratories) received FDA approval in 1997 for the diagnosis of pituitary GH deficiency. A separate formulation, Geref for injection, was used off-label for GH secretagogue therapy in pediatric short stature and adult GHD.

The landmark pediatric trial by Walker and colleagues, published in Pediatrics in 1990, was central to the clinical case for sermorelin. That study showed increased growth velocity in children with GHD treated with sermorelin acetate, providing the efficacy foundation that supported clinical use for years before and after FDA approval.

Voluntary withdrawal in 2008

In 2008, Serono's parent company EMD discontinued Geref in the United States. The withdrawal was voluntary, not safety-driven. The company cited commercial reasons, primarily the dominance of recombinant human growth hormone products in the GHD market. Once a branded product is withdrawn voluntarily and no generic manufacturer steps in, the FDA has no obligation to ensure continued access.

That gap left prescribers and patients with one pathway: 503A compounding pharmacies, which are licensed to prepare individualized prescriptions from bulk active pharmaceutical ingredients (bulk API) for named patients. Sermorelin acetate bulk API is synthesized by a small number of contract peptide manufacturers, most of them outside the United States.

FDA bulk-drug-substance lists and the 2019 to 2023 tension

The legal status of peptides in 503A compounding rests on whether the substance appears on the FDA's 503A Bulks List, a list of ingredients that may lawfully be used by traditional compounding pharmacies. Sermorelin has been evaluated by the FDA's Pharmacy Compounding Advisory Committee (PCAC) and, as of the most recent review cycle, remains available for 503A compounding because it meets the criteria: a clinical need that cannot be met by an FDA-approved alternative, and nominations supported by prescriber demand.

Between 2019 and 2023, a broader FDA crackdown on peptide compounding created significant uncertainty. Several peptides were placed on the FDA's Category 2 list (substances with insufficient safety or efficacy data to permit compounding) or removed from the 503A Bulks List entirely. BPC-157 and TB-500 were restricted. Ipamorelin and CJC-1295 faced similar scrutiny. Sermorelin itself was not banned, but the supply disruptions created by enforcement actions against peptide suppliers rippled through the compounding pharmacy system.

The WomanRx Supply-Risk Framework for Compounded Peptides:

| Risk factor | Sermorelin status | |---|---| | FDA-approved finished product available | No (since 2008) | | On 503A Bulks List | Yes (as of 2024) | | Bulk API manufactured domestically | Rarely; most API is imported | | Number of major bulk API suppliers | Estimated 3 to 5 globally | | Subject to prior FDA warning action | Indirectly (via peptide supplier audits) | | Substitute drug available if supply fails | Tesamorelin (FDA-approved, brand Egrifta) for HIV-associated lipodystrophy only |

Supply Disruptions: What Actually Happened and When

2008 withdrawal ripple

Immediately after Geref's withdrawal, compounding pharmacies absorbed demand quickly because bulk API was already available. The transition caused short-term sourcing scrambles but no sustained shortage. Most established 503A pharmacies had existing relationships with peptide API suppliers.

2019 to 2020 FDA guidance and the peptide audit wave

The FDA issued guidance in 2019 tightening oversight of bulk drug substances used in compounding. Inspection of API suppliers, particularly those based in China, increased significantly. Several peptide API batches failed certificate-of-analysis requirements for purity, particularly for related peptide impurities.

Sermorelin acetate, as a 29-amino-acid chain, is technically demanding to synthesize at pharmaceutical grade. Solid-phase peptide synthesis (SPPS) must achieve coupling efficiencies greater than 99% per residue to minimize deletion sequences and truncated peptides, which are process-related impurities. When FDA inspectors found substandard purity in batches from certain offshore suppliers, those suppliers either lost 503B registration or were voluntarily withdrawn from the US market.

Compounding pharmacies that sourced from affected suppliers faced months-long gaps while they qualified new suppliers. FDA's drug shortage database does not formally list compounded products (only finished FDA-approved drugs), so these gaps were invisible in official shortage statistics, but they were real.

2023 to 2024 GLP-1 boom side effect

The surge in demand for GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide created a secondary effect on the entire compounding pharmacy sector. Compounding facilities shifted personnel and manufacturing capacity toward high-demand GLP-1 peptides. Some facilities temporarily deprioritized sermorelin compounding. This was not a supply shortage in the raw material sense, but a manufacturing-capacity constraint that caused delays of two to six weeks at several major 503A pharmacies.

Where things stand in 2025

As of early 2025, sermorelin acetate bulk API is available from multiple qualified suppliers, and the 503A compounding pathway is intact. Supply is not in acute crisis, but the single-point-of-failure risks inherent in a compounded-only drug have not gone away. Any future FDA action against a major peptide API supplier, or any reclassification of sermorelin under 503A Bulks List review, could restart the cycle.

What Supply Gaps Mean Specifically for Women

Most shortage coverage treats sermorelin as a generic performance or anti-aging drug. For women, the stakes are more specific.

Perimenopausal women and GH axis changes

In perimenopause, the hypothalamic-pituitary axis is already in flux. Gonadotropin surges, declining progesterone, and erratic estradiol all affect the GHRH-GH-IGF-1 axis. A woman who has established a nightly sermorelin regimen and achieved stable IGF-1 levels may see those levels drop meaningfully within four to six weeks of supply interruption. Research published in the Journal of Clinical Endocrinology and Metabolism shows that IGF-1 declines with age in women accelerate after menopause transition, making maintained GH pulsatility more, not less, important at this life stage.

Women with PCOS

Women with PCOS often have higher baseline IGF-1 and altered GH pulsatility compared to women without the condition. Studies show that GH pulse frequency is elevated in PCOS, which may affect how sermorelin dosing translates in this group. Supply interruption in a woman with PCOS who is using sermorelin for off-label metabolic indications may also disrupt insulin sensitivity trajectories being monitored alongside other treatments.

Thyroid interaction

Hypothyroidism blunts GH secretion and reduces IGF-1 production. Many women treated with sermorelin also carry a diagnosis of Hashimoto's thyroiditis or subclinical hypothyroidism. If thyroid status is not optimized, sermorelin response may be markedly diminished regardless of supply continuity. A supply gap in a woman who was simultaneously adjusting her levothyroxine dose makes it almost impossible to untangle which change drove any IGF-1 shift.

Pregnancy, Lactation and Contraception: Required Reading

Sermorelin is not for use in pregnancy or breastfeeding. This section is not optional context. It is the clinical bottom line.

Pregnancy

No controlled human trials of sermorelin in pregnancy exist. Animal reproductive toxicology data are limited. The FDA had not assigned a formal pregnancy category letter to sermorelin before the category system was retired in 2015. Under the current Pregnancy and Lactation Labeling Rule (PLLR), the FDA requires labeling to disclose human and animal data separately; for compounded sermorelin there is no FDA-mandated labeling at all, meaning the prescriber and pharmacist bear the entire disclosure burden.

What is known: sermorelin stimulates GH, and GH has well-established effects on fetal growth, insulin resistance, and placental function. Altering the maternal GH-IGF-1 axis during organogenesis or fetal growth phases carries theoretical risk that cannot be dismissed in the absence of data. ACOG's guidance on medication use in pregnancy consistently emphasizes that peptide drugs require individual risk-benefit assessment with specialist input.

Any woman of reproductive age who is prescribed sermorelin should discuss reliable contraception with her provider. Sermorelin should be stopped before any planned conception attempt and before any fertility treatment cycle.

Trying to conceive

The GHRH-GH-IGF-1 axis interacts with the hypothalamic-pituitary-gonadal axis. IGF-1 has direct effects on folliculogenesis and oocyte quality. Whether sermorelin-augmented GH pulsatility benefits or harms a woman trying to conceive is genuinely unknown. Some reproductive endocrinologists use adjuvant rhGH during IVF cycles for poor responders, and sermorelin has been considered by analogy, but no clinical trial data support this use. Until data exist, the conservative position is to discontinue sermorelin at least one full menstrual cycle before starting fertility treatment.

Lactation

Sermorelin transfer into human breast milk has not been studied. GH itself does not transfer to milk in clinically significant amounts, but sermorelin as a 29-amino-acid peptide may behave differently. Given zero lactation data, the prudent clinical position is to avoid sermorelin while breastfeeding. LactMed, the NIH database of drug and lactation information, does not yet have a sermorelin entry, which is itself informative: absence of a reassuring entry is not reassurance.

Who This May Be Right For, and Who Should Wait

Reproductive years (18 to early 40s)

Women in this group who are not pregnant, not breastfeeding, and not actively trying to conceive may be candidates for sermorelin if they have documented GH deficiency or a clinical presentation consistent with GH axis dysfunction. Reliable contraception is a prerequisite, not a suggestion.

Women with PCOS, hypothyroidism, or a history of hormonal acne should discuss with their prescriber how sermorelin might interact with ongoing treatments. The GH-IGF-1 axis amplifies androgen signaling in androgen-sensitive tissues; a woman already managing elevated androgens needs this considered before starting.

Perimenopause (typically 40s to early 50s)

This is the life stage where sermorelin use in women is growing fastest, yet also the stage with the thinnest evidence base. Falling estrogen reduces GH pulse amplitude, and symptoms such as disrupted sleep, body composition changes, and fatigue overlap significantly with GH insufficiency symptoms. The risk is that a woman attributes symptoms to GH deficiency when they reflect estrogen deficiency, and sermorelin addresses neither the cause nor the symptom effectively.

A woman in perimenopause starting sermorelin should have IGF-1 measured at baseline and after 8 to 12 weeks, with clear criteria for discontinuation if IGF-1 does not respond. The Menopause Society's 2023 position statement does not address sermorelin specifically, but it underscores the primacy of evidence-based hormone therapy for menopausal symptom management before adjunctive peptides are added.

Postmenopause (after final menstrual period)

GH secretion continues to decline after menopause. By age 60, most women secrete less than half the GH volume they produced at age 30. Whether pharmacological GHRH stimulation in a postmenopausal woman produces clinically meaningful GH rises depends heavily on residual pituitary reserve, which declines with age.

Women on oral estrogen therapy face an additional pharmacokinetic variable: oral estrogen (not transdermal) increases GH binding protein and reduces hepatic IGF-1 sensitivity, meaning a postmenopausal woman on oral estradiol or conjugated equine estrogen may need a higher sermorelin dose to achieve a comparable IGF-1 response. This is the same sex-specific PK interaction documented for rhGH in adults and should be discussed with any prescriber combining sermorelin with oral HRT.

Practical Steps If You Are Affected by a Supply Gap

If your compounding pharmacy tells you sermorelin is unavailable, these steps apply.

First, ask specifically whether the shortage is a bulk API issue or a manufacturing-capacity issue. The answer changes the expected duration. API shortages linked to a supplier failing FDA inspection can last three to six months. Capacity constraints usually resolve in two to four weeks.

Second, ask whether your pharmacy has a qualified alternative supplier with current certificate-of-analysis documentation for purity (greater than 98% by HPLC), endotoxin level (less than 5 EU/mg), and sterility. You have the right to request that documentation.

Third, discuss with your prescriber whether a structured break is clinically appropriate. IGF-1 does not drop to zero overnight. A four-week gap in a woman with adequate pituitary reserve and good sleep is unlikely to cause irreversible harm. A four-month gap in a postmenopausal woman with documented severe GHD is a different clinical situation.

Fourth, do not self-substitute with unregulated "research peptide" suppliers. These products are not manufactured under pharmaceutical-grade conditions. FDA warning letters to research peptide websites document contamination, mislabeling, and sterility failures. The risk of injection site infection or systemic sepsis from a non-sterile peptide is real and not acceptable.

Monitoring Parameters Women Should Know

Your prescriber should be checking the following before and during sermorelin use.

IGF-1 at baseline and at 8 to 12 weeks. Target IGF-1 is typically the mid-normal range for age and sex. The Endocrine Society adult GHD guideline recommends targeting the middle tertile of the age- and sex-adjusted normal range, which for a 48-year-old woman is approximately 100 to 200 ng/mL depending on the laboratory.

Fasting glucose and insulin. GH is counter-regulatory to insulin. Sermorelin-driven GH elevations can transiently impair insulin sensitivity, particularly in women with PCOS or prediabetes. A baseline fasting glucose, and re-check at three months, is standard-of-care adjacent.

Thyroid function. Uncontrolled hypothyroidism blunts response. TSH and free T4 should be optimized before sermorelin is started and rechecked if response is poor.

Cortisol. Morning cortisol should be normal before sermorelin is initiated. Adrenal insufficiency and GHD can co-exist, and treating GH deficiency before cortisol deficiency is identified and treated carries risk of adrenal crisis in rare cases.